# DEPARTMENT OF JUSTICE

### **Drug Enforcement Administration**

### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated June 28, 2002, and published in the **Federal Register** on August 7, 2002, (67 FR 51294), Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Drug Tetrahydrocannabinols (7370) Difenoxin (9168) Propiram (9649) Amphetamine (1100) Methylphenidate (1724) Codeine (9050) Oxycodone (9143)	Schedule I I II II II
Hydromorphone (9150)           Hydrocodone (9193)           Meperidine (9230)           Morphine (9300)           Thebaine (9333)           Alfentanil (9737)           Sufentanil (9740)           Fentanyl (9801)	

The firm plans to manufacture the listed controlled substances in bulk to supply final dosage form manufacturers.

DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Johnson Matthey, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Johnson Matthey, Inc. on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: January 27, 2003. Laura M. Nagel, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 03–3050 Filed 2–6–03; 8:45 am] BILLING CODE 4410–09–M

# DEPARTMENT OF JUSTICE

## **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Registration

By notice dated October 21, 2002, and published in the Federal Register on
October 25, 2002, (67 FR 65604),
Polaroid Corporation, 1265 Main Street,
Building W6, Waltham, Massachusetts 02454, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of 2, 5-dimethoxyamphetamine (7396), a basic class of controlled substance listed in Schedule I.

The firm plans to manufacture 2,5dimethoxyamphetamine for conversion into a non-controlled substance.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Polaroid Corporation to manufacture 2,5dimethoxyamphetamine is consistent with the public interest at this time. DEA has investigated Polaroid Corporation to ensure that the company's registration is consistent with the public interest. The investigation included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: January 27, 2003.

#### Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03–3048 Filed 2–6–03; 8:45 am]

BILLING CODE 4410-09-M

# DEPARTMENT OF JUSTICE

### **Drug Enforcement Administration**

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated August 20, 2002, and published in the **Federal Register** on October 18, 2002, (67 FR 64419), Research Triangle Institute, Kenneth H. Davis, Jr., Hermann Building, East Institute Drive, PO Box 12194, Research Triangle Park, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Marihuana (7360)	
Cocaine (9041)	

The Institute will manufacture small quantities of cocaine derivatives and marihuana derivatives for use by their customers primarily in analytical kits, reagents and standards. No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Research Triangle Institute to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Research Triangle Institute on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: January 27, 2003.

### Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03–3051 Filed 2–6–03; 8:45 am]

BILLING CODE 4410-09-M